U.S. oncology pricing is significantly higher than a market like UK as UK has a single payer that significantly negotiates prices down of the drug doesn't get coverage. Oncology companies make the majority of their profit in the U.S.
NWBO must get approval of this Phase 3 trial or they are toast. Will all the manipulations of the trial, this is going to be a risky bet.
The TTF functions by disrupting fast growing cells from growing and those are aggressive cancer cells. The more compliant patients are at wearing the TTF device, the higher the survival rate. The newer TTF devices are more targeted and have higher TTF levels. So far there has not been evidence that the risks of any adverse effect is greater than the benefits of life saving benefits. The highest adverse event by far has been skin irritations from the TTF device and the gel that is used.
Market Data 
Markets 
AI
